A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity

Published:2020-11 Issue: Volume:493 Page:91-101
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Tao Huimin,Cheng Lu,Liu Lihua,Wang Hong,Jiang Zhijie,Qiang Xu,Xing Lijun,Xu Yifeng,Cai Xinying,Yao Jing,Wang Min,Qiu Zheng

Funder

National Natural Science Foundation of China

China Pharmaceutical University

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Improved survival with Ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010

2. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death;Ishida;EMBO J.,1992

3. PD-1 and its ligands in tolerance and immunity;Keir;Annu. Rev. Immunol.,2008

4. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat. Rev. Canc.,2012

5. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors;Hargadon;Int. Immunopharmcol.,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1/PD-L1 Axis in the Tumor Microenvironment;Bioconjugate Chemistry;2024-07-09

2. Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy;Molecular Pharmaceutics;2024-03-27

3. PD‐1: A critical player and target for immune normalization;Immunology;2024-01-25

4. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy;Acta Pharmaceutica Sinica B;2023-12

5. Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress;European Journal of Pharmacology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3